Thrombus resolution with tirofiban in the conservative management of patients presenting with plaque erosion

Coronary Artery Disease
Tomoyo SugiyamaIk-Kyung Jang

Abstract

Recent studies suggest that conservative management with antithrombotic therapy without stenting may be an option in selected patients with acute coronary syndrome (ACS). We evaluated whether a glycoprotein IIb/IIIa inhibitor, tirofiban, would offer additional benefit in patients with plaque erosion presenting with ACS who were treated with antiplatelet therapy without stenting. Forty-nine patients who completed 1-year follow-up optical coherence tomography imaging in the EROSION study were divided into two groups: tirofiban (n=32) versus no tirofiban (n=17). Thrombus volume, thrombus burden, and the incidence of major adverse cardiovascular events were evaluated. At baseline, the tirofiban group had similar thrombus volume [3.73 (1.27-12.49) vs. 3.51 (1.70-8.65) mm, P=0.983] and marginally greater thrombus burden [17.9 (10.1-26.1) vs. 10.6 (6.8-19.0)%, P=0.097]. At 1 month, the tirofiban group had smaller residual thrombus volume [0.00 (0.00-1.78) vs. 0.94 (0.07-4.20) mm, P=0.054], thrombus burden [0.0 (0.0-6.4) vs. 7.0 (1.8-14.8)%, P=0.024], and greater reduction of thrombus volume (85.4±24.6 vs. 67.1±27.1%, P=0.021). These differences were maintained up to 1 year. Complete resolution of thrombus at 1 month was more frequent ...Continue Reading

References

Apr 4, 1985·The New England Journal of Medicine·UNKNOWN TIMI Study Group
May 16, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·R VirmaniS M Schwartz
Apr 25, 2006·Journal of the American College of Cardiology·Renu VirmaniFrank D Kolodgie
Jun 13, 2006·The American Journal of Cardiology·Teruyoshi KumeKiyoshi Yoshida
Apr 1, 2008·JAMA : the Journal of the American Medical Association·Marco ValgimigliUNKNOWN Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in
Mar 12, 2013·JACC. Cardiovascular Imaging·Francesco PratiJagat Narula
Apr 30, 2014·Nature Reviews. Cardiology·Fumiyuki OtsukaJagat Narula
Jun 7, 2014·Circulation Research·Deepak L BhattRobert A Harrington
Jan 17, 2015·Investigative Ophthalmology & Visual Science·Michaël J A GirardNicholas G Strouthidis
Jan 31, 2015·Atherosclerosis·Kazuyuki YahagiRenu Virmani
Jul 19, 2015·Vascular Pharmacology·Shawn KingCassidy Harmon
Jul 1, 2015·Interventional Cardiology Clinics·Daniel S Ong, Ik-Kyung Jang

❮ Previous
Next ❯

Citations

Sep 22, 2020·Journal of Thrombosis and Thrombolysis·Osamu KuriharaIk -Kyung Jang
Oct 24, 2019·Journal of the American Heart Association·Erika YamamotoIk-Kyung Jang
Jul 6, 2021·European Heart Journal. Case Reports·Isabel Muñoz PousaVictor A Jiménez Díaz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.